keyword
MENU ▼
Read by QxMD icon Read
search

Aromatase and breast cancer

keyword
https://www.readbyqxmd.com/read/28204994/prevalence-of-aromatase-inhibitor-induced-arthralgia-in-breast-cancer-a-systematic-review-and-meta-analysis
#1
REVIEW
David Beckwée, Laurence Leysen, Kaipo Meuwis, Nele Adriaenssens
BACKGROUND: Although aromatase inhibitors have proven to be an effective treatment of hormone receptor-positive breast cancer in postmenopausal women, aromatase inhibitor-induced arthralgia (AIA) is an adverse event associated with low compliance with treatment. The aim of this literature study is to assess the prevalence of AIA and to provide an overview of significant predictors for the development of AIA. METHODS: A systematic review was conducted using PubMed, Cochrane Library and Web of Science...
February 15, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28195993/subcutaneous-testosterone-letrozole-therapy-before-and-concurrent-with-neoadjuvant-breast-chemotherapy-clinical-response-and-therapeutic-implications
#2
Rebecca L Glaser, Anne E York, Constantine Dimitrakakis
OBJECTIVE: Hormone receptor-positive breast cancers respond favorably to subcutaneous testosterone combined with an aromatase inhibitor. However, the effect of testosterone combined with an aromatase inhibitor on tumor response to chemotherapy was unknown. This study investigated the effect of testosterone-letrozole implants on breast cancer tumor response before and during neoadjuvant chemotherapy. METHODS: A 51-year-old woman on testosterone replacement therapy was diagnosed with hormone receptor-positive invasive breast cancer...
February 13, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/28187491/estrone-and-estradiol-levels-in-breast-cancer-patients-using-anastrozole-are-not-related-to-body-mass-index
#3
Eduardo Borges Coscia, Maricene Sabha, Marli Gerenutti, Francisco Carlos Groppo, Cristiane de Cássia Bergamaschi
Objective Obesity is associated with an increased risk for breast cancer. Recent studies have shown that aromatase inhibitors may be less effective in women with a high body mass index (BMI). The aim of this study was to establish the relationship between the BMI and plasma estrone and estradiol levels in postmenopausal women with hormone receptor-positive breast cancer using anastrozole. Methods In this cohort study, the patients were divided into three groups according to BMI (normal weight, overweight and obese) to compare and correlate plasma hormone levels before starting anastrozole hormone therapy and three months after treatment...
February 10, 2017: Revista Brasileira de Ginecologia e Obstetrícia
https://www.readbyqxmd.com/read/28185173/ovarian-function-suppression-in-premenopausal-women-with-early-stage-breast-cancer
#4
REVIEW
Matteo Lambertini, Lucia Del Mastro, Giulia Viglietti, Noam F Pondé, Cinzia Solinas, Evandro de Azambuja
Breast cancers arising in young women are biologically more aggressive, and most of these patients are candidates to receive aggressive treatments that include the use of chemotherapy. As most of these tumors express the hormone receptors (i.e., luminal disease), these patients are also candidates to adjuvant endocrine therapy. Chemotherapy-induced amenorrhea showed to be prognostic in young patients with luminal breast cancer. However, the role of ovarian function suppression (OFS) in addition to standard adjuvant treatments has been largely debated over the past years...
January 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28177754/comparison-of-the-effects-of-nobiletin-and-letrozole-on-the-activity-and-expression-of-aromatase-in-mcf-7-breast-cancer-cell-line
#5
Seyedeh Tayebeh Rahideh, Mohammad Keramatipour, Mitra Nourbakhsh, Fariba Koohdani, Mostafa Hoseini, Saeed Talebi, Farzad Shidfar
Nobiletin (NOB) is one of the polymethoxyflavones mainly found in citrus fruits. Aromatase or cytochrome P450 (CYP19) enzyme catalyzes the last and rate-limiting step in estrogen biosynthesis. This study was carried out to investigate the effect of NOB on the activity and expression of aromatase and compare this property with letrozole (LET) as aromatase inhibitor in MCF-7 breast cancer cell line. The cell viability was assessed by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assays...
February 1, 2017: Biochemistry and Cell Biology, Biochimie et Biologie Cellulaire
https://www.readbyqxmd.com/read/28177277/prevalence-of-bisphosphonate-therapy-in-women-with-breast-cancer-treated-with-aromatase-inhibitors-in-germany%C3%A2
#6
Louis Jacob, Karel Kostev, Peyman Hadji
PURPOSE: The aim of this study is to analyze the prevalence of bisphosphonate therapy in women with breast cancer (BC) treated with aromatase inhibitors (AI) in Germany. METHODS: We included women with BC who started AI therapy between January 2005 and December 2014 (index date) and were followed for a maximum of 24 months. The number of women who received at least one prescription of bisphosphonate during AI therapy was calculated. RESULTS: A total of 6,959 women with BC who received AI therapy between 2005 and 2014 were analyzed...
February 8, 2017: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28176175/safety-and-immunogenicity-of-neoadjuvant-treatment-using-wt1-immunotherapeutic-in-combination-with-standard-therapy-in-patients-with-wt1-positive-stage-ii-iii-breast-cancer-a-randomized-phase-i-study
#7
M Higgins, G Curigliano, V Dieras, S Kuemmel, G Kunz, P A Fasching, M Campone, T Bachelot, P Krivorotko, S Chan, A Ferro, L Schwartzberg, M Gillet, P M De Sousa Alves, V Wascotte, F F Lehmann, P Goss
PURPOSE: This Phase I, multicenter, randomized study (ClinicalTrials.gov NCT01220128) evaluated the safety and immunogenicity of recombinant Wilms' tumor 1 (WT1) protein combined with the immunostimulant AS15 (WT1-immunotherapeutic) as neoadjuvant therapy administered concurrently with standard treatments in WT1-positive breast cancer patients. METHODS: Patients were treated in 4 cohorts according to neoadjuvant treatment (A: post-menopausal, hormone receptor [HR]-positive patients receiving aromatase inhibitors; B: patients receiving chemotherapy; C: HER2-overexpressing patients on trastuzumab-chemotherapy combination; D: HR-positive/HER2-negative patients on chemotherapy)...
February 7, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28174265/sgk3-sustains-er%C3%AE-signaling-and-drives-acquired-aromatase-inhibitor-resistance-through-maintaining-endoplasmic-reticulum-homeostasis
#8
Yuanzhong Wang, Dujin Zhou, Sheryl Phung, Charles Warden, Rumana Rashid, Nymph Chan, Shiuan Chen
Many estrogen receptor alpha (ERα)-positive breast cancers initially respond to aromatase inhibitors (AIs), but eventually acquire resistance. Here, we report that serum- and glucocorticoid-inducible kinase 3 (SGK3), a kinase transcriptionally regulated by ERα in breast cancer, sustains ERα signaling and drives acquired AI resistance. SGK3 is up-regulated and essential for endoplasmic reticulum (EnR) homeostasis through preserving sarcoplasmic/EnR calcium ATPase 2b (SERCA2b) function in AI-resistant cells...
February 7, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28167101/quinone-related-hexacyclic-by-products-in-the-production-process-of-exemestane
#9
Giovanni Battista Giovenzana, Norberto Masciocchi, Roberto Negri, Giovanni Palmisano, Andrea Penoni, Lucio Toma
Exemestane, a 3rd-generation aromatase inhibitor, is clinically used in the treatment of breast cancer in postmenopausal women. The key step of the industrial synthetic process, i.e., a dehydrogenation to introduce the Δ(1)-unsaturation, is normally performed with quinones such as p-chloranil or DDQ. We observed the formation of two different hexacyclic by-products, depending on the quinone used in the oxidation step. These compounds arise from an initial [4+2] cycloaddition between the precursor 6-methylenandrost-4-ene-3,17-dione and the quinone reagent, followed by a twofold dehydrohalogenation (with p-chloranil) or dehydrogenation (with DDQ)...
February 3, 2017: Steroids
https://www.readbyqxmd.com/read/28163101/identification-of-mirnas-as-biomarkers-for-acquired-endocrine-resistance-in-breast-cancer
#10
Penn Muluhngwi, Carolyn M Klinge
Therapies targeting estrogen receptor α (ERα) including tamoxifen, a selective estrogen receptor modulator (SERM) and aromatase inhibitors (AI), e.g., letrozole, have proven successful in reducing the death rate for breast cancer patients whose initial tumors express ERα. However, about 40% of patients develop acquired resistance to these endocrine treatments. There is a critical need to develop sensitive circulating biomarkers that accurately identify signaling pathways altered in breast cancer patients resistant to endocrine therapies...
February 2, 2017: Molecular and Cellular Endocrinology
https://www.readbyqxmd.com/read/28162365/-557-auricular-point-acupressure-to-manage-aromatase-inhibitor-induced-arthralgia-in-postmenopausal-breast-cancer-survivors
#11
C Yeh, W Lin, L Wood, D Bovbjerg, G van Londen
No abstract text is available yet for this article.
April 2016: Journal of Pain: Official Journal of the American Pain Society
https://www.readbyqxmd.com/read/28155606/clinical-utility-of-neoadjuvant-endocrine-therapy-for-hormone-receptor-positive-breast-cancer
#12
Hans-Christian Kolberg, Bahriye Aktas, Cornelia Liedtke
Primary endocrine therapy is an option in cases of hormone receptor positive and HER2 negative non-metastatic breast cancer. Aromatase inhibitors are considered therapy of choice in postmenopausal patients. In premenopausal patients aromatase inhibitors in combination with LHRH-analogues are regarded superior to tamoxifen. Three different settings have to be discriminated: • Patients too frail for surgery are candidates for primary endocrine therapy in order to control the disease. Treatment duration is determined by the course of the disease...
February 1, 2017: Reviews on Recent Clinical Trials
https://www.readbyqxmd.com/read/28155053/weight-changes-in-postmenopausal-breast-cancer-survivors-over-2%C3%A2-years-of-endocrine-therapy-a-retrospective-chart-review
#13
Kirsten A Nyrop, Allison M Deal, Jordan T Lee, Hyman B Muss, Seul Ki Choi, Samara Dixon, Amy Wheless, Lisa A Carey, Shlomit S Shachar
PURPOSE: Obesity and weight gain after breast cancer (BC) diagnosis can affect cancer outcomes. This study explores the question of weight change during the first 2 years of endocrine treatment (ET) to identify the independent effects of BC diagnosis and treatment on post-diagnosis weight trajectories in early-stage postmenopausal BC survivors. METHODS: The study design is a retrospective chart review. Chi square tests and ANOVA were used to compare patients who gained >2 kg, lost >2 kg, or had stable weight...
February 2, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28152790/what-is-the-health-related-quality-of-life-for-women-with-metastatic-breast-cancer
#14
Amye Tevaarwerk, Hans-Peter Goertz, Mary Lou Smith, Preeti S Bajaj, Elda Railey, Carolina Reyes
: 70 Background: Metastatic breast cancer (MBC) and its treatments can have a significant impact on patients' health-related quality of life (HRQoL) and daily functioning. To better assess the impact of MBC on HRQoL, we conducted an online survey among women with MBC. METHODS: We developed and administered a cross-sectional, web-based survey, and invited registered members of three advocacy groups currently living with MBC to participate. Respondents completed an informed consent and completed assessments on symptom burden using an overall QOL question (1 item), the MD Anderson Symptom Inventory Survey (MDASI), activities of daily living (ADLs, Rotterdam Scale), and impacts on work productivity...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28148596/longitudinal-changes-in-volumetric-breast-density-with-tamoxifen-and-aromatase-inhibitors
#15
Natalie J Engmann, Christopher Scott, Matthew R Jensen, Lin Ma, Kathleen R Brandt, Amir Mahmoudzadeh, Serghei Malkov, Dana H Whaley, Carrie Hruska, Fang-Fang Wu, Stacey Winham, Diana L Miglioretti, Aaron D Norman, John Heine, John Shepherd, Vernon S Pankratz, Celine M Vachon, Karla Kerlikowske
BACKGROUND: Reductions in breast density with tamoxifen and aromatase inhibitors may be an intermediate marker of treatment response. We compare changes in volumetric breast density among breast cancer cases using tamoxifen or aromatase inhibitors (AI) to untreated women without breast cancer. METHODS: Breast cancer cases with a digital mammogram prior to diagnosis and after initiation of tamoxifen (n=366) or AI (n=403), and a sample of controls (n=2170) were identified from the Mayo Clinic Mammography Practice and San Francisco Mammography Registry...
February 1, 2017: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/28144163/association-between-telomere-length-and-cyp19-ttta-repetition-polymorphism-in-healthy-and-breast-cancer-diagnosed-women
#16
Blanca Murillo-Ortiz, Sandra Martínez-Garza, David Suárez García, Rosa Del Carmen Castillo Valenzuela, Juan Francisco García Regalado, Gerardo Cano Velázquez
INTRODUCTION: Several studies have reported an increase in breast cancer (BC) risk when patients are carriers of the CYP19 TTA polymorphism with ≥10 repeats; moreover, it has been reported that telomere length is associated with a higher susceptibility of developing cancer. OBJECTIVE: The objective of this study was to understand the relationship between CYP19 TTTA repetition polymorphism and telomere length and its effects on serum estradiol, estrone and follicle-stimulating hormone (FSH)...
2017: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28133219/-a-case-of-recurrent-inflammatory-breast-cancer-treated-using-multidisciplinary-therapy
#17
Takashi Katsumori, Hiromitsu Hamaguchi, Shinichi Yamamoto, Yukika Tsukamoto, Hisami Ohshima, Susumu Ohkawara, Shigetaka Shimada
The patient was a 65-year-old woman who underwent segmental mastectomy for left breast cancer 5 years ago. The pathological diagnosis ofthe tumor was noninvasive ductal carcinoma, TisN0M0 and Stage 0. Postoperative radiation therapy was performed, but chemotherapy and hormone therapy were not administered. The patient presented with redness of the residual left breast. Skin biopsy showed lymphatic invasion of adenocarcinoma, and the patient was diagnosed with inflammatory carcinoma ofthe breast. After 4 cycles ofAC followed by 4 cycles ofdocetaxel, the mass was diminished and the redness disappeared...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28126832/effect-of-%C3%AE-agonist-on-the-dexamethasone-induced-expression-of-aromatase-by-the-human-monocyte-cells
#18
Masatada Watanabe, Shuji Ohno, Hiroshi Wachi
Emerging evidence suggests that sex steroids are important for human skin health. In particular, estrogen improves skin thickness, elasticity, and moisture of older women. The major source of circulating estrogen is the ovary; however, local estrogen synthesis and secretion have important roles in, for example, bone metabolism and breast cancer development. We hypothesized that infiltrated peripheral monocytes are one of the sources of estrogen in skin tissues. We also hypothesized that, during atopic dermatitis under stress, a decline in the hypothalamus-pituitary-adrenal axis (HPA) and facilitation of the (hypothalamus)-sympathetic-adrenomedullary system (SAM) attenuates estrogen secretion from monocytes...
January 26, 2017: Endocrine Connections
https://www.readbyqxmd.com/read/28122888/response-to-ovarian-stimulation-is-not-impacted-by-a-breast-cancer-diagnosis
#19
Molly M Quinn, Hakan Cakmak, Joseph M Letourneau, Marcelle I Cedars, Mitchell P Rosen
STUDY QUESTION: Does a breast cancer diagnosis impact ovarian function in the setting of fertility preservation? SUMMARY ANSWER: Ovarian reserve and ovarian stimulation outcomes are similar in patients with a new diagnosis of breast cancer and patients undergoing elective fertility preservation. WHAT IS KNOWN ALREADY: Prior studies, with small study populations, lack of controlling for individual differences in ovarian reserve and infertile controls, have reported conflicting outcomes for cancer patients undergoing ovarian stimulation for fertility preservation...
January 24, 2017: Human Reproduction
https://www.readbyqxmd.com/read/28117994/novel-selective-estrogen-receptor-downregulators-serds-developed-against-treatment-resistant-breast-cancer
#20
Rui Xiong, Jiong Zhao, Lauren M Gutgesell, Yueting Wang, Sue Lee, Bhargava Karumudi, Huiping Zhao, Yunlong Lu, Debra A Tonetti, Gregory R J Thatcher
Resistance to the selective estrogen receptor modulator tamoxifen and to aromatase inhibitors that lower circulating estradiol occurs in up to 50% of patients, generally leading to an endocrine-independent ER+ phenotype. Selective ER downregulators (SERDs) are able to ablate ER and thus, theoretically, to prevent survival of both endocrine-dependent and -independent ER+ tumors. The clinical SERD fulvestrant is hampered by intramuscular administration and undesirable pharmacokinetics. Novel SERDs were designed using the 6-OH-benzothiophene (BT) scaffold common to arzoxifene and raloxifene...
February 10, 2017: Journal of Medicinal Chemistry
keyword
keyword
48353
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"